Table II.
Multivariate Cox regression analyses of OS and PFS for patients with cervical cancer.
| OS | PFS | |||
|---|---|---|---|---|
| Prognostic variables | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age (>50 vs. ≤50 years) | 2.272 (0.820–6.297) | 0.115 | 2.273 (0.888–5.817) | 0.087a |
| SCC level (>1.5 vs. ≤1.5 ng/ml) | 1.624 (0.163–4.673) | 0.542 | 1.984 (0.354–4.763) | 0.733 |
| FIGO Stage (>I vs. ≤I) | 1.506 (0.590–3.846) | 0.392 | 1.258 (0.535–2.960) | 0.599 |
| Tumor size (>4 vs. ≤4cm) | 1.258 (0.509–3.109) | 0.619 | 1.090 (0.456–2.607) | 0.846 |
| Differentiation (Grade 3 vs. 1/2) | 1.045 (0.416–2.621) | 0.926 | 1.516 (0.633–3.630) | 0.350 |
| Histological type (SCC vs. AC) | 2.906 (1.013–8.339) | 0.057 | 2.129 (0.782–5.792) | 0.139 |
| LN Metastasis (+ vs. -) | 4.078 (1.755–9.474) | 0.001 | 3.454 (1.579–7.559) | 0.002a |
| Msi2 expression (high vs. low) | 3.105 (1.139–8.465) | 0.027 | 3.181 (1.274–7.941) | 0.013a |
a
P<0.05; OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; Msi2, Mousasi 2; SCC, squamous cell carcinoma; FIGO, International Federation of Gynecology and Obstetrics; AC, adenocarcinoma; LN, lymph node.